All In Biotech

NDA 019614 · Azurity

Verelan

Verapamil Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Oct 1, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1990

May 29, 1990

Approved uses

1

Original approval plus efficacy supplements

Registered trials

143

16 Phase 3, 13 recruiting

FAERS reports

4,312

3,916 serious, 958 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 27, 2024.

INDICATIONS AND USAGE Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide...

Mechanism: Mechanism of Action Essential Hypertension Verapamil HCl exerts antihypertensive effects by decreasing systemic vascular resistance, usually without orthostatic decreases in blood pressure or reflex tachycardia; bradycardia (rate less than 50 beats/minute is uncommon). Verapamil HCl regularly reduces arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing the total peripheral resistance (afterload) against which the heart works.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 29, 1990 Original approval · Type 3 - New Dosage Form
4 products under this application
  • VERELAN · VERAPAMIL HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • VERELAN · VERAPAMIL HYDROCHLORIDE 360MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • VERELAN · VERAPAMIL HYDROCHLORIDE 240MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • VERELAN · VERAPAMIL HYDROCHLORIDE 180MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Verapamil" as an intervention, any sponsor and status, largest first.

All 143 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea357
  • nausea353
  • drug interaction316
  • dizziness293
  • hypotension287
  • fatigue277
  • diarrhoea271
  • abdominal pain245
  • vomiting244
  • cough242
  • headache238
  • fall237

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200482
2005130
2006122
200758
200890
200953
201086
201179
2012112
201361
2014109
2015160
2016187
2017187
2018199
2019217
2020243
2021273
2022488
2023407
2024438
2025331
2026200

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,740 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.